CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer

NCT01218867 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

24

Enrollment

NIH

Sponsor class

Stopped No objective responses were observed.

Conditions

Metastatic Cancer
Metastatic Melanoma
Renal Cancer

Interventions

BIOLOGICAL: Anti-VEGFR2 CAR CD8 plus PBL
DRUG: Cyclophosphamide
BIOLOGICAL: Aldesleukin
DRUG: Fludarabine

Sponsor

National Cancer Institute (NCI)